<DOC>
	<DOC>NCT01202773</DOC>
	<brief_summary>The primary purpose of this study is to help answer if LY2127399 is safe and effective in the treatment of rheumatoid arthritis in patients with an inadequate response to one or more Tumor necrosis factor-alpha (TNF α) inhibitors. This study is comprised of 2 periods: Period 1 - 24 week blinded treatment Period 2 - 48 week post treatment follow up</brief_summary>
	<brief_title>A Study in Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Diagnosis of Rheumatoid Arthritis (RA) of more than 6 months and less than 15 years At least 8 tender and swollen joints An abnormally high Creactive protein (CRP) level or erythrocyte sedimentation rate (ESR) Positive for Rheumatoid Factor (RF) or Anticyclic citrullinated peptide (CCP) antibody Previously treated with biologic TNFα inhibitor therapy (infliximab, certolizumab, golimumab, etanercept, adalimumab) and stopped treatment due to insufficient efficacy or intolerance Regular use of at least one conventional diseasemodifying antirheumatic drug (DMARD), with a stable dose for at least 8 weeks prior to study start Woman must not be pregnant, breastfeeding, or become pregnant during the study Use of unstable doses of nonsteroidal inflammatory drugs (NSAIDS) in the past 6 weeks Steroid injection or intravenous (IV) infusion in the last 6 weeks Use of more than 10 mg/day of oral steroids in the last 6 weeks History of a serious reaction to other biological DMARDs Use of an oral calcineurin inhibitor (e.g., cyclosporin or tacrolimus) in the last 8 weeks Surgery on a joint or other major surgery less than 2 months ago, or plans to have joint surgery or major surgery during the study Active fibromyalgia, juvenile chronic arthritis, spondyloarthropathy, Crohn's disease, ulcerative colitis, psoriatic arthritis, or other systemic inflammatory condition except RA Cervical cancer or squamous skin cancer within the past 3 years, or other cancer within the past 5 years Received a live vaccine received within the past 12 weeks (for example, vaccines for measles, mumps, rubella, and chicken pox, and nasalspray flu vaccines) Hepatitis or human immunodeficiency virus (HIV) A serious bacterial infection (for example, pneumonia or cellulitis) within 3 months or a serious bone or joint infection within 6 months Symptoms of herpes zoster or herpes simplex within the last month Active or latent tuberculosis (TB) Current symptoms of a serious disorder or illness Use of an investigational drug within the last month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
</DOC>